Nizatidine, intended for the short-term treatment of duodenal ulcers and benign gastric ulcers, was found to contain the impurity N-nitrosodimethylamine.
The affected lots were distributed to wholesalers, mail order pharmacies and retail pharmacies between June 2017 and August 2018.
Mylan said it hasn’t received any adverse event reports related to the recall.
Read the full news release here.
More articles on pharmacy:
Walgreens secures enterprisewide specialty accreditation
Drug price hike update: Merck, Allergen, Novartis raise prices
Regeneron restructures, cuts at least 15 jobs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.